Evidence map›Paper›PMID 39192159›Full record

ArticleActa neurologica Belgica2025

Central nervous system complications during treatment in childhood acute leukemia.

Arzu Ekici, Bilgen Ayan, Elif Güler Kazancı, Zeynep Beyza Kuşku, Cengiz Gökhan Orcan, Cengiz Havalı, Sevil Dorum, Taha Metin, Betül Biner Orhaner

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neurologica Belgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Arzu EkiciDepartment of Pediatrics, Division of Neurology, Bursa Yuksek Ihtisas Training and Research Hospital, Mimar Sinan Avenue, Yıldırım, Bursa, Turkey. drarzuekici@gmail.com.ORCID http://orcid.org/0000-0002-0813-7189
Bilgen AyanDepartment of Pediatrics, Division of Hematology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.ORCID http://orcid.org/0000-0003-3469-8040
Elif Güler KazancıDepartment of Pediatrics, Division of Hematology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.ORCID http://orcid.org/0000-0003-0910-1142
Zeynep Beyza KuşkuDepartment of Pediatrics, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.ORCID http://orcid.org/0000-0002-8729-6478
Cengiz Gökhan OrcanDepartment of Radiology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.ORCID http://orcid.org/0000-0003-2970-8021
Cengiz HavalıDepartment of Pediatrics, Division of Neurology, Bursa Yuksek Ihtisas Training and Research Hospital, Mimar Sinan Avenue, Yıldırım, Bursa, Turkey.ORCID http://orcid.org/0000-0001-6275-0884
Sevil DorumDepartment of Pediatrics, Division of Metabolism, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.ORCID http://orcid.org/0000-0001-6947-2573
Taha MetinDepartment of Pediatrics, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.ORCID http://orcid.org/0000-0001-9507-2792
Betül Biner OrhanerDepartment of Pediatrics, Division of Hematology, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey.ORCID http://orcid.org/0000-0002-4452-9518

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCentral nervous system (CNS) complications can be seen in patients with leukemia, depending on the disease itself and the chemotherapeutic agents used. This study focused on CNS complications during treatment in children with acute leukemia in a single pediatric institution.

methodsCNS complications were evaluated retrospectively in 115 patients with ALL and AML. Patients with CNS leukemia infiltration at the time of diagnosis or during a neurological event, late-onset encephalopathy, peripheral neuropathy, or a previous history of neurological abnormalities were excluded from the study.

resultsA total of 115 children's clinical records with acute leukemia over a four-year period were reviewed. Acute CNS complications developed in 23.1% of acute myeloid leukemia (AML) patients and in 13.5% of acute lymphoblastic leukemia (ALL) patients. CNS complications developed most frequently during the induction phase of the treatment (66.7%). Seizures were the most common symptom (9 patients, 50%), followed by hemiparesis (4 patients, 22.2%) and headache (4 patients, 22.2%). Six patients (33.3%) had chemotherapy-induced toxic leukoencephalopathy, two (11.1%) had Wernicke's encephalopathy, and one patient (5.6%) each had sinus vein thrombosis, posterior reversible encephalopathy syndrome, and CNS infection. Sequelae occurred in three patients (16.7%), and only one patient (5.6%) died due to a CNS complication.

conclusionA wide variety of symptoms can be observed in childhood leukemia, depending on the disease itself, the chemotherapeutic agents used and a lot of other conditions such as nutritional problems. Our research shows that several CNS complications might manifest with similar symptoms; differentiated diagnosis between the underlying etiological reasons can be made by neuroimaging.

Indexed as

Antineoplastic AgentsCentral Nervous System DiseasesLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleHumansInfantMaleRetrospective StudiesAntineoplastic AgentsAcute lymphoblastic leukemiaAcute myeloid leukemiaCentral nervous system complicationsChildren

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.